Abiopharma

New Form 8-K - Claritev Corp Filed: 2025-09-03 AccNo: 0001793229-25-000151 Size: 6 MB Item 7.01: Regulation FD Disclosure

New Form 8-K - PALVELLA THERAPEUTICS, INC. Filed: 2025-09-03 AccNo: 0001104659-25-086685 Size: 12 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

Wave Life Sciences Announces Positive Update from Ongoing RestorAATion-2 Trial of WVE-006 in Alpha-1 Antitrypsin Deficiency

Shock Top and Auntie Anne’s® Make It Official - Beer Kneads Pretzels

Vaxcyte Advances VAX-31 Infant Phase 2 Dose-Finding Study with First Participants Receiving VAX-31 Optimized Dose

Bioventus to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

TG Therapeutics Announces Completion of Existing Share Repurchase Program and Authorization of New $100 Million Program

Apogee Therapeutics to Participate at the Stifel 2025 Virtual Immunology and Inflammation Forum

enGene Achieves Target Enrollment Milestone for LEGEND Trial Pivotal Cohort

Cybin - Cybin to Participate in the Cantor Global Healthcare Conference 2025

BridgeBio to Host Autosomal Dominant Hypocalcemia Type 1 (ADH1) Investor Webinar on Wednesday, September 10th at 8:00 am ET

XOMA Royalty to Present at H.C. Wainwright 27th Annual Global Investment Conference

XOMA Royalty to Present at H.C. Wainwright 27th Annual Global Investment Conference

Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer’s Disease Reaches 75% Enrollment Target

Cybin to Participate in the Cantor Global Healthcare Conference 2025